Theraloc (nimotuzumab) for high grade glioma: the manufacturer withdrawed its marketing application
EMEA press release about the marketing authorization withdrawal for the monoclonal antibody nimotuzumab (Theraloc): Oncoscience AG withdraws its application for Theraloc (nimotuzumab) The European Medicines Agency (EMEA) has been formally notified by Oncoscience AG of its decision to withdraw its application for a centralised marketing authorisation for the medicine Theraloc (nimotuzumab), 5 mg/ml concentrate for solution for […]
Cisplatin mechanism of action: 3-D video animation
Mechanism of Action. Cisplatin, carboplatin, and oxaliplatin enter cells by diffusion, and by an active Cu2+ transporter (Kruh, 2003). Inside the cell, the chloride atoms of cisplatin may be displaced and the compound may be inactivated directly by reaction with nucleophiles such as thiols. Chloride is replaced by water, yielding a positively charged molecule. In […]
Tapentadol approved by FDA as treatment for moderate to severe pain
FDA news release about the approval of pentadol to alleviate moderate to severe Pain: The U.S. Food and Drug Administration has approved Tapentadol hydrochloride, an immediate-release oral tablet for the relief of moderate to severe acute pain. Tapentadol is a centrally-acting synthetic analgesic that is available in doses of 50 mg, 75 mg, or 100 […]
Imatinib (Gleevec) pharmacology: mechanism of action and therapeutic considerations
Imatinib mesylate is a small-molecule tyrosine kinase inhibitor that was initially developed as a 2-phenylaminopyrimidine derivative specific for PDGFR. Imatinib was subsequently found to be a potent inhibitor of ABL kinases, including the BCR-ABL fusion protein generated as a result of the t(9;22) chromosomal translocation (Philadelphia chromosome) found in chronic myelogenous leukemia (CML), and was […]